Read the full OHTAC Recommendation Report
Pharmacogenomics is the study of how genes affect a person’s response to drugs. Advances in the understanding of common genetic variations have made it possible for doctors to begin to use information about a person’s genetic makeup to help choose drugs and drug doses that are likely to work best for that person.
This is a new science and so far only a small number of drugs, mostly for cancer treatment, have been identified to be used in this way. But the field is growing quickly and many more drugs are being tested for their pharmacogenomic properties.
In 2011, the Ontario Health Technology Advisory Committee gathered information about emerging pharmacogenomics testing. Of the many drugs being tested, the Committee came up with a list of those that should be given priority in Ontario for upcoming health technology assessment.
Multi-Gene Expression Profiling for Guiding Adjuvant Chemotherapy Decisions in Women With Early Breast Cancer: OHTAC Recommendation (PDF)
Gene Expression Profiling for Guiding Adjuvant Chemotherapy Decisions in Women with Early Breast Cancer: An Evidence-Based and Economic Analysis (PDF)
KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: OHTAC Recommendation (PDF)
KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis (PDF)
Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: OHTAC Recommendation (PDF)
Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis (PDF)
Use of this site, and the interpretation of the information contained here, is subject to important terms and conditions. Use of this site and information except in accordance with these terms and conditions is expressly prohibited.
The Ministry of Health and Long-Term Care has provided the following response: The Genetics Testing Advisory Committee was established in April 2014 with a three-year mandate to review the clinical utility and validity of genetic tests and provide advice to the Ministry of Health and Long-Term Care on the provision of genetic tests in Ontario. Some of the functions of the committee, including the responsibility to make recommendations about which tests receive public funding, will be transferred to Health Quality Ontario after the Genetic Testing Advisory Committee’s three year mandate is complete.
As part of our core function to promote health care supported by the best available evidence, we use established scientific methods to analyze the evidence for a wide range of health interventions, including diagnostic tests, medical devices, interventional and surgical procedures, health care programs and models of care. These analyses are informed by input from a range of individuals, including patients and clinical experts. The Ontario Health Technology Advisory Committee — a committee of the Health Quality Ontario board of directors — reviews the evidence and makes recommendations about whether health care interventions should be publicly funded or not. Draft recommendations are posted on the Health Quality Ontario website for feedback. Final recommendations are approved by our board of directors and then shared with the Ministry of Health and Long-Term Care. For more detailed information, visit our Evidence to Improve Care pages.
Sign up for our newsletter to receive monthly notifications of when draft recommendations are open for feedback
Patients, families and the public are central to improving health quality.
Are you passionate about quality health care for all Ontarians? Stay in-the-know about our newest programs, reports and news.